WEBVTT

0e561837-1c21-448b-ab53-e83f6bfb816b-0
00:00:00.120 --> 00:00:02.485
Stefan,
thank you so much for joining me today to

0e561837-1c21-448b-ab53-e83f6bfb816b-1
00:00:02.485 --> 00:00:04.000
talk about Breakthrough Science.

63c8d345-a9c5-4bae-8ac2-63ea95edcdb4-0
00:00:04.720 --> 00:00:05.760
It's a pleasure to be here.

8a001df2-0f9e-45f6-a927-06b3c4ab5292-0
00:00:06.800 --> 00:00:10.858
So, you at Bayer,
more specifically your impact investment

8a001df2-0f9e-45f6-a927-06b3c4ab5292-1
00:00:10.858 --> 00:00:16.567
arm LEAPS has launched the study together
with BCG to look at how public sentiment

8a001df2-0f9e-45f6-a927-06b3c4ab5292-2
00:00:16.567 --> 00:00:21.932
across the world looks at science and
technology and specifically a number of

8a001df2-0f9e-45f6-a927-06b3c4ab5292-3
00:00:21.932 --> 00:00:27.160
the very forward-looking forefront
technologies that you're also active in.

61cd17f2-a333-4df0-8a62-3ab4b6da3661-0
00:00:27.960 --> 00:00:33.494
So, we surveyed 13,000 people,
and one of the most surprising findings

61cd17f2-a333-4df0-8a62-3ab4b6da3661-1
00:00:33.494 --> 00:00:37.625
was the overwhelming optimism,
across all countries,

61cd17f2-a333-4df0-8a62-3ab4b6da3661-2
00:00:37.625 --> 00:00:43.003
about the promise and potential of
science and technology to improve

61cd17f2-a333-4df0-8a62-3ab4b6da3661-3
00:00:43.003 --> 00:00:44.639
individuals' futures.

3fcb1f18-c069-4cb3-b697-40701c4e3b4d-0
00:00:45.080 --> 00:00:47.480
75% of of respondents said that.

a331cd1f-6cbe-4b2c-b62d-11bdc54005e6-0
00:00:48.040 --> 00:00:51.009
So,
what motivated you at Bayer to start such

a331cd1f-6cbe-4b2c-b62d-11bdc54005e6-1
00:00:51.009 --> 00:00:53.720
an effort and do research into that topic?

d0d3c3d3-e36c-4b2c-9070-c725000d36fb-0
00:00:55.120 --> 00:00:58.966
First and foremost,
we're a science-based company and we live

d0d3c3d3-e36c-4b2c-9070-c725000d36fb-1
00:00:58.966 --> 00:01:03.867
in a world where the progress in science
has never been as fast as it has been

d0d3c3d3-e36c-4b2c-9070-c725000d36fb-2
00:01:03.867 --> 00:01:04.240
today.

9cf8f593-4999-47be-a9ea-1d6980ecdda2-0
00:01:04.480 --> 00:01:07.063
So,
there is no better moment in history than

9cf8f593-4999-47be-a9ea-1d6980ecdda2-1
00:01:07.063 --> 00:01:09.760
actually to engage into these new
technologies.

09a74f00-3e70-47c6-9cf9-59ac6152562c-0
00:01:10.720 --> 00:01:13.150
So,
we ask people about their perceptions on

09a74f00-3e70-47c6-9cf9-59ac6152562c-1
00:01:13.150 --> 00:01:17.255
a whole range of new technologies,
cell and gene and in healthcare in terms

09a74f00-3e70-47c6-9cf9-59ac6152562c-2
00:01:17.255 --> 00:01:18.120
of therapeutics.

79f5a7b8-bae0-4efc-963a-56e759971b0e-0
00:01:18.440 --> 00:01:22.000
We ask about AI in healthcare and how
that can change healthcare delivery.

2cf3fc1f-dfbd-46ab-b44a-e44c466aedd0-0
00:01:22.360 --> 00:01:27.080
We're also asked about cultured meat and
new genomic techniques in, in agriculture.

221e5416-1a28-474c-99bb-394addef07b2-0
00:01:27.680 --> 00:01:30.152
Overall,
it's a lot easier for people to feel

221e5416-1a28-474c-99bb-394addef07b2-1
00:01:30.152 --> 00:01:34.343
optimistic about cell and gene and in
therapeutics than about a couple of the

221e5416-1a28-474c-99bb-394addef07b2-2
00:01:34.343 --> 00:01:34.720
others.

a3881b2d-ad95-460b-936f-e40cd22f3dd1-0
00:01:35.160 --> 00:01:38.802
But even on new genomic technologies in
agriculture,

a3881b2d-ad95-460b-936f-e40cd22f3dd1-1
00:01:38.802 --> 00:01:44.370
over 50% of respondents in both developed
and developed nations were positive in

a3881b2d-ad95-460b-936f-e40cd22f3dd1-2
00:01:44.370 --> 00:01:44.920
general.

78db1ef2-a5f2-4045-af12-40d736255c29-0
00:01:45.280 --> 00:01:50.315
And then as soon as people thought about
the benefits in terms of more climate

78db1ef2-a5f2-4045-af12-40d736255c29-1
00:01:50.315 --> 00:01:55.160
resistant crops fighting world hunger,
actually that support went up a lot.

547b8e41-4ed5-46bd-834b-89aff09bee3b-0
00:01:55.600 --> 00:01:57.957
So,
what do you conclude from that for the

547b8e41-4ed5-46bd-834b-89aff09bee3b-1
00:01:57.957 --> 00:02:01.355
business opportunity,
but also for the dialogue you'd like to

547b8e41-4ed5-46bd-834b-89aff09bee3b-2
00:02:01.355 --> 00:02:02.999
happen in in the public arena?

1ed231d4-a019-47f6-91b7-6ee276dd2755-0
00:02:03.600 --> 00:02:06.902
First of all,
I do see that across a wide array of

1ed231d4-a019-47f6-91b7-6ee276dd2755-1
00:02:06.902 --> 00:02:10.139
people in society,
there's more support for these

1ed231d4-a019-47f6-91b7-6ee276dd2755-2
00:02:10.139 --> 00:02:12.600
technologies, including policy makers.

743195eb-8f9f-4fda-9e45-8a2eaec24fae-0
00:02:12.640 --> 00:02:14.440
There's also a better information.

e74aa569-9d63-486f-8a96-7346154e65cb-0
00:02:14.640 --> 00:02:19.817
And that's something that we also owe to
the public about what these technologies

e74aa569-9d63-486f-8a96-7346154e65cb-1
00:02:19.817 --> 00:02:24.680
can do and also dispel some of the myths,
negative myths that surround them.

90172c8a-6a88-4c57-9d39-8b263e423345-0
00:02:25.680 --> 00:02:30.179
If we come back to healthcare and cell
and gene therapies and healthcare,

90172c8a-6a88-4c57-9d39-8b263e423345-1
00:02:30.179 --> 00:02:35.105
one of the questions we asked people was
we know these are technologies that are

90172c8a-6a88-4c57-9d39-8b263e423345-2
00:02:35.105 --> 00:02:36.200
costly to develop.

b447e106-ef71-4ae3-8db2-b59c25ba8319-0
00:02:36.600 --> 00:02:38.160
They, they will be expensive.

9ee6f0d9-16b7-4f45-ac1c-3bed12e95798-0
00:02:38.240 --> 00:02:42.160
They will be not accessible for a big
part of the population at first.

64bc4358-5e89-4ac3-b413-f9d3e6d312cc-0
00:02:42.600 --> 00:02:47.091
Yet 60% of respondents were still very
supportive because they felt that is what

64bc4358-5e89-4ac3-b413-f9d3e6d312cc-1
00:02:47.091 --> 00:02:49.476
it,
what it's going to take to advance the

64bc4358-5e89-4ac3-b413-f9d3e6d312cc-2
00:02:49.476 --> 00:02:49.920
science.

d9307e37-6c29-430e-a110-0a91c0b1c908-0
00:02:50.240 --> 00:02:54.440
How do you look at that in some of our
forefront technologies in our industry?

57aa8251-ff8e-4cba-b60d-56112c32f032-0
00:02:54.800 --> 00:02:58.440
Is inequality of access unavoidable or
how do you see that develop?

e799106b-e33d-477f-aa1b-934891332ce0-0
00:02:58.440 --> 00:03:01.625
I think,
I think we need to think about modalities

e799106b-e33d-477f-aa1b-934891332ce0-1
00:03:01.625 --> 00:03:05.185
of payment in,
in different access schemes and there are

e799106b-e33d-477f-aa1b-934891332ce0-2
00:03:05.185 --> 00:03:10.306
solutions to this because when you have a
one shot therapy that actually solves a

e799106b-e33d-477f-aa1b-934891332ce0-3
00:03:10.306 --> 00:03:13.367
problem,
instead of going into chronic therapies

e799106b-e33d-477f-aa1b-934891332ce0-4
00:03:13.367 --> 00:03:18.613
where you have to pay for years and years,
including all the costs of care that are

e799106b-e33d-477f-aa1b-934891332ce0-5
00:03:18.613 --> 00:03:19.800
associated to that.

9ad7e7d5-cdae-492f-9b18-5527172b67a8-0
00:03:20.160 --> 00:03:24.586
We have to look at a total cost and we
need to come up with modalities to

9ad7e7d5-cdae-492f-9b18-5527172b67a8-1
00:03:24.586 --> 00:03:26.920
actually finance these novel therapies.

18936b3a-85b6-48e4-a95c-2412fc4ff041-0
00:03:26.920 --> 00:03:30.912
So, it's not about spending more,
it's actually about becoming more

18936b3a-85b6-48e4-a95c-2412fc4ff041-1
00:03:30.912 --> 00:03:33.320
efficient in the way how we provide care.

554a25b4-2127-405e-b553-d3ad8f6541cd-0
00:03:33.840 --> 00:03:35.973
Stefan,
thank you so much for joining me today

554a25b4-2127-405e-b553-d3ad8f6541cd-1
00:03:35.973 --> 00:03:36.200
here.

9a2a3a65-0c08-4d16-8af8-ccde4c2fe593-0
00:03:37.160 --> 00:03:37.640
You're welcome.